A2780ADR Cell Line human

93112520, human ovary, Epithelial

• 别名: A2780-ADR Cells
• 分類程式碼代碼: 41106514

属性

• product name: A2780ADR Cell Line human, 93112520
• 生物源: human ovary
• 描述: Human Caucasian ovarian carcinoma
• 增長模式: Adherent
• 染色體組型: Not specified
• 形態學: Epithelial
• 產品: Not specified
• 受體: Not specified
• 技術: cell culture | mammalian: suitable
• 相關疾病: cancer
• 運輸包裝: dry ice
• 儲存溫度: −196°C

说明

細胞系來源

Human Caucasian ovarian carcinoma

細胞系描述

The adriamycin-resistant cell line A2780ADR has been developed by exposure of the parent A2780 cell line (Sigma catalogue no. 93112519) to adriamycin. A2780ADR is cross-resistant to melphalan and vinblastine. To retain resistance adriamycin has to be added to the media. The cells grow as a monolayer and in suspension in spinner cultures and are tumourigenic in immune deficient mice. Together with the cisplatin-resistant variant A2780cis these lines only differ in their exposure to a single drug and should facilitate the search for molecular changes responsible for the expression of pleiotropic drug resistance in human ovarian cancer.

應用

Study of drug transport, toxicity testing, drug resistance cancer studies

DNA分析

STR-PCR Data: Amelogenin: X
CSF1PO: 10,11
D13S317: 13
D16S539: 11,14
D5S818: 11,12
D7S820: 10
THO1: 6
TPOX: 8,9
vWA: 15,16

培養基

RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS); treatment with 10E-7 M adriamycin at least once a week.

例行更新培養

Split sub-confluent cultures (70-80%) 1:5 to 1:10 i.e. seeding at 5x1,000 to 2x10,000 cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C. Recommendation: culture cells without drug after resuscitation until growth has been fully established.

其他說明

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

免責聲明

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.